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February 21, 2006:884–92estricted to secondary CVD events during the first year after
ischarge from rehab and which had included coronary artery
evascularization procedures besides myocardial infarction, stroke,
nd CVD death as end points, we also had observed a decreased
isk in patients who never smoked (odds ratio [OR]  0.44), who
eported former smoking (OR  0.64), and who were categorized
s recent quitters (OR  0.71) in comparison with continued
mokers. The current study, which is based on a much longer
ollow-up, an exclusive focus on “hard” disease endpoints, and the
se of repeated measurements of smoking status, suggests that
ertinent risk reductions may be even stronger in the long run.
The proportions of cotinine-positive subjects in the group of
elf-reported never smokers at rehab (6%) and at one-year
ollow-up (9%) may serve as estimates for the proportion of
eceivers (persons misreporting their smoking status). Although
alse-positive test results cannot be ruled out, exposure to environ-
ental tobacco smoke, which may have a major impact on
rognosis, is unlikely to cause a serum cotinine level as high as our
utpoint (4). The finding that 20% of patients changed smoking
tatus in the first year of follow-up further underlines the
elatively high dynamics of smoking status shortly after the
ccurrence of CHD.
We conclude that the impact of smoking abstinence on long-
erm prognosis of patients with CHD may be considerably larger
han suggested by previous studies which relied on self-reports of
moking status. Our results underline the importance of efforts to
upport smoking cessation and to prevent relapse in patients with
oronary heart disease.
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nti-Inflammatory Action of
ngiotensin-Converting Enzyme Inhibitors
nd Angiotensin Receptor Blockers
he meta-analysis by Healey et al. (1) indicated that both
ngiotensin-converting enzyme inhibitors (ACEIs) and angioten-
in receptor blockers (ARBs) appear to be effective in the preven-
ion of atrial fibrillation. However, among the plausible underlying
echanisms, they did not mention the potential role of low-grade
ystemic inflammation.
Increasing levels of C-reactive protein (CRP), the classic marker
f systemic inflammation, have been shown to be associated with
trial fibrillation (2,3). Furthermore, CRP appears also to predict
atients at increased risk for developing future atrial fibrillation (4).
Because angiotensin receptor blockade has been shown to be
elated to a decrease in markers of systemic inflammation (5,6),
his anti-inflammatory action may help explain the beneficial effect
f ACEIs and ARBs in the prevention of atrial fibrillation.
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revention of Atrial Fibrillation by
ngiotensin-Converting Enzyme Inhibitors
nd Angiotensin II Receptor Blockers
e read with great interest the report by Healey et al. (1) in which
hey presented a meta-analysis of published randomized trials involv-
ng the prevention of atrial fibrillation (AF) with angiotensin-
